What are the newer options for patients who fail first- and second-generation TKI therapies?

Patient FAQs published on October 9, 2015
Download Transcript Download Audio
What are the newer options for patients who fail first- and second-generation TKI therapies?
Prior to the turn of the century, there were limited options for patients with chronic myeloid leukemia. It was interferon, a nasty injectable medication or bone marrow transplant, but at the turn of the century, the development of the so-called tyrosine kinase inhibitors, pills that can control the disease, became available, with most patients now having response and becoming long-term survivors. Over the last 15 years, we developed multiple medications. So, your doctor now has choices between different pills to control your disease and to fit in best with your side-effect profile. Therefore, if you are having a side effect, talk to your doctor because they may want to tweak the dose or even change the therapy so that you can continue on your medications and have a good response. In addition, we have now developed a non-TKI therapy, an injection that can be given for patients with very advanced disease who are not responding to conventional therapies.

MediCom Worldwide, Inc. acknowledges the collaborative support from The Leukemia & Lymphoma Society (LLS).

Additional Resources
www.LLS.org/CML - CML webpage with links to resources
www.LLS.org/booklets - Chronic Myeloid Leukemia (booklet) and Chronic Myeloid Leukemia Guide(easier to read booklet)
www.LLS.org/PCR - Financial Assistance for PCR test
www.LLS.org/educationvideos - Two videos - CML: The Role of PCR Testing and Resistant Myeloid Leukemia
www.myPCR.org - Coalition of CML-focused organizations provides information about PCR, campaign to increase awareness of the need to monitor CML treatment, and resources for patients.

Last modified: April 4, 2016